Oral contraceptives and thrombosis. From risk estimates to health impact

Acta Obstetricia et Gynecologica Scandinavica

Volumn 78, Issue 2, 1999, Pages 142-149

  Lidegaard, Øjvind ^a   Bygdeman, Marc ^b   Milsom, Ian ^c   Nesheim, Britt Ingjerd ^d   Skjeldestad, Finn Egil ^e   Toivonen, Juhani ^f  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f JORVI HOSPITAL   (Finland)

Author keywords

Cerebral thrombosis; Disability; Mortality; Myocardial infarction; Oral contraceptives; Second generation progestagens; Third generation progestagens; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ACUTE HEART INFARCTION; AGE; ARTERY THROMBOSIS; ARTICLE; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; HYPERTENSION; MIGRAINE; MORTALITY; OBESITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; STROKE; THROMBOSIS; VARICOSIS; VEIN THROMBOSIS;

EID: 0032902248     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1080/j.1600-0412.1999.780213.x     Document Type: Article

References (41)

1. 1. World Health Organization Collaborative Study on cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82.
2. 2. World Health Organization Collaborative Study on cardiovascular disease and steroid hormone contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8.
3. 3. Poulter NR, Farley RMM, Chang CL, Marmot MG, Meirik O. Safety of combined oral contraceptive pills [Letter]. Lancet 1996; 347: 547.
4. 4. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6.
5. 5. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of ideopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
6. 6. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83-8.
7. 7. Lewis AM, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational research. Contraception 1996; 54: 5-13.
8. 8. Mills A. Combined oral contraception and the risk of venous thromboembolism. Hum Reprod 1997; 12: 2595-8.
9. 9. Skjeldestad FE. Increased number of induced abortions in Norway after the media coverage of adverse vascular events from the use of third-generation oral contraceptives. Contraception 1997; 55: 11-14.
10. 10. Ramsay S. UK 'pill scare' led to abortion increase. Lancet 1996; 347: 1109.
11. 11. Milsom I, Odlind V, Hedberg C, Lidegaard Ø. Alarming increase in the number of abortions. Does fear of thrombosis limit the use of oral contraceptives?. Läkertidningen 1997; 94: 4731-6.
12. 12. Statistics Finland: Statistical yearbook of Finland 1997; 92: 440.
13. 13. Lidegaard Ø, Milsom I. The pill. The controversy continues. Acta Obstet Gynecol Scand 1996; 75: 93-7.
14. 14. Lidegaard Ø, Milsom I. Oral contraceptives and thrombotic diseases: Impact of new epidemiological studies. Contraception 1996; 53: 135-9.
15. 15. Westhoff CL. Oral contraceptives and venous thromboembolism: Should epidemiologic associations drive clinical decision making? Contraception 1996; 54: 1-3.
16. 16. Speroff L. Oral contraceptives and venous thromboembolism. Int J Gynaecol Obstet 1996; 54: 45-50.
17. 17. Heinemann LAJ, Lewis M, Assmann A, Cravens L, Guggenmoos-Holzmann I. Could preferential prescribing and referral behavior of physicians explain the elevated thrombotic risk found to be associated with third generation oral contraceptives? Drug Saf 1996; 5: 285-94.
18. 18. Farley TMM, Meirik O, Poulter NR, Chang CL, Marmot MG. Oral contraceptives and thrombotic diseases: Impact of new epidemiological studies. Contraception 1996; 54: 193-5.
19. 19. Vandenbroucke JP, Rosendaal FR. End of the line for 'third-generation-pill' controversy? Lancet 1997; 349: 1113-14.
20. 20. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR. Third-generation oral contraceptives and deep venous thrombosis: From epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 1997; 177: 887-91.
21. 21. Lidegaard Ø. The influence of thrombotic risk factors when oral contraceptives are prescribed. Acta Obstet Gynecol Scand 1997; 76: 252-60.
22. 22. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception 1998; 57: 291-301.
23. 23. Herings RMC, Boer DA, Urquhart J, Leufkens HGM. Non-causal explanations for the increased risk of venous thromboembolism among users of third-generation oral contraceptives. Pharmacoepidemiool Drug Safety 1996; 5: S88.
24. 24. Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-8.
25. 25. Vandenbroucke JP, Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR. Mortality from venous thromboembolism and myocardial infarction in young women in The Netherlands. Lancet 1996; 348: 401-2.
26. 26. Thomas SHL. Mortality from venous thromboembolism and myocardial infarction in young adults in England and Wales. Lancet 1996; 348: 402.
27. 27. Andersen BS, Steffensen FH, Sørensen HT, Nielsen GL, Olsen J. The cumulative incidence of venous thromboembolism during pregnancy and puerperium - An 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand 1998; 77: 170-3.
28. 28. Rosing J, Tans G, Nicolaes GAF, Thomassen MCLGD, Oerle RV, Ploeg PMENVD et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second-and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
29. 29. Douketis JD, Ginsberg JS, Holbrook A, Crowther M, Duku EK, Burrows RF. A reevaluation of the risks for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Int Med 1997; 157: 1522-30.
30. 30. Lewis MA, Spitzer WO, Heinemann LAJ, MacRae KD, Bruppacher R, Thorogood M. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. BMJ 1996; 312: 88-90.
31. 31. Lewis M, Heinemann LAJ, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Contraception 1997; 56: 129-40.
32. 32. Jick H, Jick SS, Myers MW, Vasilakis C. Risk of acute myocardial infarction and low-dose combined oral contraceptives. [Letter]. Lancet 1996; 347: 627-8.
33. 33. WHO. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997; 349: 1202-9.
34. 34. Lidegaard Ø, Edström B. Oral contraceptives and myocardial infarction. A case-control study. [Abstract]. Eur J Contraception Reprod Health Care, suppl 1, 72-3.
35. 35. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996; 348: 498-505.
36. 36. Heinemann LAJ, Lewis MA, Thorogood M, Spitzer WO, Guggenmoss-Holzmann I, Bruppacher R. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from international study on oral contraceptives and health of young women. BMJ 1997; 315: 1502-4.
37. 37. Lidegaard Ø, Kreiner S. Cerebral thrombosis and oral contraceptives. Contraception 1998; 57: 303-14.
38. 38. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996; 335: 8-15.
39. 39. Schwartz SM, Siscovick DS, Longstreth WT et al. Use of low-dose oral contraceptives and stroke in young women. Ann Int Med 1997; 127: 596-603.
40. 40. Lidegaard Ø. Thrombotic diseases in young women and the influence from oral contraceptives. Am J Obstet Gynecol 1998, in press.
41. 41. WHO. Cardiovascular disease and steroid hormone contraception. WHO Technical Report Series 877. Geneva, 1998.